Abbott is launching a new digital health app to assist consumers with effective pain management.
Chronic pain can negatively impact personal relationships, work productivity, and a person’s daily routine.
Today, the company announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.
Neurostimulation works by altering pain signals as they travel to the brain.
It is a pain management therapy that delivers electrical stimulation to the spinal cord, dorsal root ganglion (a cluster of nerve cells in the spinal cord), and brain.
Using an implantable device, or neurostimulator, this treatment aims to reduce the user’s perception and experience of certain types of pain inside the body.
During the device trial period required before the permanent implant, the app allows patients to record their pain and well-being outcomes while trialing their neurostimulation therapy.
NeuroSphere myPath will be compatible with Abbott’s Proclaim™ XR SCS System for patients living with chronic pain in the trunk and limbs and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.
The NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in Q2 2021.
